Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular (18)F-FDG Uptake in Atherosclerotic Mice

This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of (18)F-fluorodeoxyglucose in atherosclerotic mice. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Ståhle, Mia, Silvola, Johanna M.U., Hellberg, Sanna, de Vries, Margreet, Quax, Paul H.A., Kroon, Jeffrey, Rinne, Petteri, de Jong, Alwin, Liljenbäck, Heidi, Savisto, Nina, Wickman, Anna, Stroes, Erik S.G., Ylä-Herttuala, Seppo, Saukko, Pekka, Abrahamsson, Tommy, Pettersson, Knut, Knuuti, Juhani, Roivainen, Anne, Saraste, Antti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188869/
https://www.ncbi.nlm.nih.gov/pubmed/32368695
http://dx.doi.org/10.1016/j.jacbts.2020.01.008
Descripción
Sumario:This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of (18)F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.

Ejemplares similares